TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26077620
Drug: Treatment delivery
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment delivery method (T‐CBT vs FtF‐CBT)
Study: 18353632
Drug: Recent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recent treatment protocols with higher cumulative doses or increased dose intensity of alkylators and epipodophyllotoxins and the use of G-CSF
Study: 18353632
Drug: Earlier treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Earlier treatment protocols
Study: 18353632
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment for ESFT
Study: 12620695
Drug: Prior antihypertensive
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior antihypertensive treatment
Study: 11137246
Drug: High-dose hepatitis
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose hepatitis A and B vaccine (2 doses at month 0 and 6)
Study: 11137246
Drug: Twinrix (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twinrix (3 doses at month 0, 1, and 6)
Study: 11137246
Drug: High-dose hepatitis
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose hepatitis A and B vaccine
Study: 8482290
Drug: Long prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long prednisone therapy (60 mg/m2 per 24 h for 6 weeks, followed by alternate day 40 mg/m2 per 48 h for 6 weeks)
Study: 8482290
Drug: Standard prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard prednisone therapy (60 mg/m2 per 24 h for 4 weeks, followed by 40 mg/m2 per 48 h for 4 weeks)
Study: 8482290
Drug: Long prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long prednisone therapy
Study: 3434601
Drug: Models administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Models administration of three-dimensional constructional praxis tests
Study: 3434601
Drug: Photographs administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Photographs administration of three-dimensional constructional praxis tests
Study: 3434601
Drug: Drawings administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drawings administration of three-dimensional constructional praxis tests
Study: 29306481
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment + 25(OH)D3 supplementation
Study: 29306481
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with 25(OH)D levels ≤ 50 nmol/L
Study: 29306481
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with 25(OH)D levels > 50 nmol/L
Study: 26685099
Drug: Oral sucrose
Normalized name: TootSweet 24% Oral Sucrose Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sucrose combined with NNS (group NS)
Study: 26685099
Drug: Oral sucrose
Normalized name: TootSweet 24% Oral Sucrose Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sucrose combined with swaddling (group SS)
Study: 26685099
Drug: Oral sucrose
Normalized name: TootSweet 24% Oral Sucrose Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sucrose combined with NNS and swaddling (group NSS)
Study: 26685099
Drug: Oral sucrose
Normalized name: TootSweet 24% Oral Sucrose Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sucrose (routine care, group S)
Study: 23733781
Drug: MRD assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRD assessment after induction therapy in non-intensive-pathway patients
Study: 19641202
Drug: Oral artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral artesunate at a dose of 2 mg/kg/day for 7 days
Study: 19641202
Drug: Artesunate at
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate at a dose of 4 mg/kg/day for 3 days followed by mefloquine at a total dose of 25 mg/kg
Study: 19725966
Drug: Artesunate monotherapy
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate monotherapy
Study: 19641202
Drug: Artesunate-mefloquine therapy
Normalized name: artesunate and mefloquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate-mefloquine therapy
Study: 11167792
Drug: TAD-HAM (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAD-HAM (high-dose AraC, mitoxantrone)
Study: 8152203
Drug: Cefixime 8
Normalized name: cefixime 8 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime 8 mg/kg bodyweight once daily
Study: 3048643
Drug: DDP (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDP (100 mg/m2; day 1)
Study: 3048643
Drug: DDP +
Normalized name: DDP-200
DrugBank: DDP-200 (DB05919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDP + 5-fluorouracil (1 g/m2 continuous infusion for 5 days)
Study: 26385357
Drug: Pilates exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilates exercise (60-minute class, twice weekly for 12 weeks)
Study: 19412946
Drug: CLE (37.7,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLE (37.7, 150, 200 mg)
Study: 19412946
Drug: CL-CR (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: CL-CR (50 and 200 mg)
Study: 3269553
Drug: Psychodynamic conflict-centered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychodynamic conflict-centered therapy (n = 34)
Study: 3269553
Drug: Client-centered therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Client-centered therapy (n = 34)
Study: 29623516
Drug: L-thyroxine (L-T4)
Normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-thyroxine (L-T4) treatment (0.5-3.0 g/(kg·d))
Study: 29623516
Drug: Placebo (non-L-T4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (non-L-T4 treatment)
Study: 18268081
Drug: OPT-80 (100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPT-80 (100, 200, 300, and 450 mg)
Study: 18268081
Drug: OPT-80 (150,
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPT-80 (150, 300, or 450 mg)
Study: 29866386
Drug: Contingent vouchers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contingent vouchers (CV) for smoking abstinence (twice‐daily carbon monoxide [CO] readings)
Study: 27181260
Drug: Corticosteroids with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids with gradually reduced dosage (control group).
Study: 22897408
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g activated charcoal by mouth every 4 hours
Study: 15973546
Drug: Increased central
Normalized name: Rauwolfia alkaloids, centrally acting antiadrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased central pressure augmentation (AG)
Study: 10650901
Drug: High-dose loperamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose loperamide (initial dose of 4 mg followed by 4 mg every 8 h, total dose 16 mg/24 h)
Study: 10650901
Drug: High-dose loperamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose loperamide
Study: 22367416
Drug: Training group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training group (n=8) - 10-week hip strengthening programme, twice weekly
Study: 20152960
Drug: E-mail therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: E-mail therapy
Study: 14998110
Drug: Behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatment (Beh)
Study: 11265923
Drug: Routine community
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine community care (CC)
Study: 11265923
Drug: Intensive behavioral
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive behavioral treatment (Beh)
Study: 9505740
Drug: Vecuronium (0.02,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium (0.02, 0.025, or 0.03 mg kg‐1)
Study: 9505740
Drug: Atracurium (0.075,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium (0.075, 0.01, or 0.0125 mg.kg‐1)
Study: 9505740
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 1 x ED95 of vecuronium + 1 x ED95 of atracurium
Study: 7849235
Drug: Cefuroxime 1500
Normalized name: cefuroxime 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime 1500 mg IV
Study: 7849235
Drug: Cefuroxime 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime 1000 mg IV
Study: 7849235
Drug: Flucloxacillin 2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flucloxacillin 2000 mg IV
Study: 7849235
Drug: Flucloxacillin 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flucloxacillin 1500 mg IV
Study: 7849235
Drug: Flucloxacillin 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flucloxacillin 1000 mg IV
Study: 1437767
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate (Zincteral) 200 mg 4 times daily for 12 months
Study: 1437767
Drug: D-penicillamine (Cuprenil-Polfa)
DrugBank: Penicillamine (DB00859)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D-penicillamine (Cuprenil-Polfa) 1.0-1.5 g daily
Study: 31598823
Drug: Intravenous phenylephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous phenylephrine (PE) bolus of 1 µg kg−1
Study: 25828745
Drug: Hypomethylating agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypomethylating agents (HMA) therapy (median of 12 courses, range 1-24)
Study: 25828745
Drug: Hypomethylating agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypomethylating agents (HMA) therapy (12 cycles or more)
Study: 25828745
Drug: Hypomethylating agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypomethylating agents (HMA) therapy (fewer than 12 cycles)
Study: 23417031
Drug: Valsartan (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (up to 160mg daily)
Study: 21036583
Drug: Olive leaf
Normalized name: OLIVE LEAF
DrugBank: Olea europaea leaf (DB14745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive leaf extract (500 mg twice daily)
Study: 21036583
Drug: Captopril (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (12.5 mg twice daily, titrated to 25 mg if necessary)
Study: 18080399
Drug: Maraviroc combined
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maraviroc combined with optimized background therapy (OBT)
Study: 11442282
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg extended phenytoin sodium capsules (Lot 1)
Study: 11442282
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg extended phenytoin sodium capsules (Lot 2)
Study: 11442282
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg extended phenytoin sodium capsules (Lot 3)
Study: 11442282
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg extended phenytoin sodium capsules (all lots)
Study: 11442282
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg extended phenytoin sodium capsules (females)
Study: 2841053
Drug: enalapril 5-20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril 5-20 mg/day
Study: 31400077
Drug: Biological causal
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological causal explanation
Study: 29896844
Drug: Supervised physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised physical training (two weekly sessions for 26 weeks)
Study: 28253045
Drug: Preoperative physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative physical activity counseling for 6 weeks, encouraging daily walking at moderate intensity in bouts ≥ 10 minutes during morning hours
Study: 22204173
Drug: Transcutaneous Electrical
Normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous Electrical Nerve Stimulation (TENS) therapy
Study: 22204173
Drug: Constant mode
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant mode of TENS therapy
Study: 22204173
Drug: Burst mode
Approvals — FDA: no, EMA: no, PMDA: no
Description: Burst mode of TENS therapy
Study: 19759166
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg soy hypocotyl aglycone isoflavones plus calcium and vitamin D
Study: 16463415
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy in a warm, waist-high pool (3 weekly sessions for 12 weeks)
Study: 16463415
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy in a warm, waist-high pool
Study: 11281054
Drug: Low-dose mutant
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose mutant tissue-type plasminogen activator (mt-PA), monteplase, 80 x 10(4) U bolus
Study: 11281054
Drug: Low-dose mutant
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose mutant tissue-type plasminogen activator (mt-PA), monteplase
Study: 11281054
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no administration of mt-PA)
Study: 9548608
Drug: Balloon stopflow
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balloon stopflow infusion combined with micro‐embolization
Study: 9548608
Drug: Stopflow infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stopflow infusion of the celiac axis combined with microspheres
Study: 9548608
Drug: Intra-arterial infusion
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial infusion with tumor adjusted concentrations
Study: 7923966
Drug: Oral 1,25(OH)2D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 1,25(OH)2D3
Study: 31517597
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (received free radon and air nicotine test kits, report back, telephone support, and $600 voucher for mitigation)
Study: 31517597
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (with high radon levels at baseline)
Study: 27918762
Drug: 8-week alternating
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8-week alternating treatment schedule of pazopanib 800 mg/d and everolimus 10 mg/d (rotating arm)
Study: 27918762
Drug: Continuous pazopanib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous pazopanib 800 mg/d (control arm)
Study: 19452582
Drug: Ropivacaine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine infusion at port sites
Study: 11167672
Drug: Nasal drops
Normalized name: Nasal Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal drops (800 microg doses)
Study: 11167672
Drug: Nasal spray
Normalized name: Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray (800 microg doses)
Study: 8385022
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (13C labelled) at doses between 12.5 and 100 mg
Study: 3708186
Drug: Doxapram (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxapram (0.5 mg X kg‐1 lean body mass bolus followed by 1 mg X min‐1 infusion)
Study: 31239638
Drug: Dexmedetomidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.5 µg/kg in 20 mL of normal saline
Study: 24424627
Drug: Conventional radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional radiotherapy (RT) - Group 3 (three-dimensional conformal treatment plan)
Study: 19535697
Drug: Licorice gargle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licorice gargle (0.5 g licorice in water)
Study: 17211432
Drug: High antibody
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High antibody concentration donors
Study: 17211432
Drug: Low-specific antibody
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-specific antibody concentration donors
Study: 29386413
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D therapy, 50000 IU intramuscularly (IM) monthly for 6 months
Study: 24906244
Drug: ALVAC-HIV and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALVAC-HIV and AIDSVAX B/E prime-boost regimen (vaccine)
Study: 7516191
Drug: GM-CSF (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF (two daily subcutaneous injections of 54 or 108 micrograms)
Study: 794520
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no antibacterial agent)
Study: 28615271
Drug: Supervised moderate-to-high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised moderate-to-high intensity aerobic exercise (1 hour, 3 times weekly for 16 weeks)
Study: 16710711
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (300 mg/day) plus vitamin C (500 mg/day) for 12 weeks
Study: 16710711
Drug: Technical anaesthesiology
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technical anaesthesiology staff before antioxidant treatment
Study: 8836715
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment including ESWL, EHL, and intracorporeal laser lithotripsy
Study: 8268363
Drug: Norfloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin (400 mg, orally, twice daily for 3 days)
Study: 8268363
Drug: Placebo (orally,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (orally, twice daily for 3 days)
Study: 22420584
Drug: Enteral methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral methadone (MG)
Study: 7806038
Drug: Interferon alfa
Normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa (10 MU/m2 three times weekly for 12 weeks)
Study: 1941387
Drug: Erythropoietin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (200 units/kg every other day for 10 doses)
Study: 19670810
Drug: Phosphomycin (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphomycin (a single 3.0 g dose)
Study: 15239141
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) 0.2 g/kg body weight daily + Soybean oil (SO) 0.8 g/kg body weight daily (n = 24)
Study: 15239141
Drug: Soybean oil
Normalized name: Soybean Oil
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soybean oil (SO) 1.0 g/kg body weight daily (n = 20)
Study: 15239141
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) treatment
Study: 2974781
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin by means of a pen injector (Insuject‐X)
Study: 31267292
Drug: Fluoxetine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (mean dose 11.8 mg/day)
Study: 30379222
Drug: Goal-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed therapy group with 8h of intensive treatment to maximize oxygen delivery
Study: 27460471
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health optimized diet (low in carbohydrates, rich in Omega‐3 fatty acids, vitamins C and D, antioxidants, and fiber) for four weeks
Study: 23312487
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen cream (0.3mg/day)
Study: 18276723
Drug: Chest physical
Normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chest physical therapy plus standard treatment for pneumonia
Study: 18276723
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for pneumonia alone
Study: 9324343
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy with PBSC support (Regimen A: etoposide, carboplatinum 1.95 g/m2, cyclophosphamide 5 g/m2, thiotepa 300 mg/m2; Regimen A': carmustine 600 mg/m2 replacing cyclophosphamide; Regimen B: etoposide, carboplatinum 1.95 g/m2, cyclophosphamide 7 g/m2, thiotepa 900 mg/m2)
Study: 3549397
Drug: Acellular pertussis
Normalized name: Acellular pertussis vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular pertussis vaccine (Biken) containing F-HA and pertussis toxin toxoid; specific dosage and duration not mentioned.
Study: 3549397
Drug: Plain whole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain whole cell vaccine; specific dosage and duration not mentioned.
Study: 3549397
Drug: Acellular pertussis
Normalized name: Acellular pertussis vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular pertussis vaccine (Biken) with aluminium phosphate as adjuvant; specific dosage and duration not mentioned.
Study: 31295174
Drug: Protease inhibitor-based
Normalized name: Protease inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor-based antiretroviral treatment (ART) regimen
Study: 31295174
Drug: Both ART
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both ART regimens (protease inhibitor-based and ZDV)
Study: 26342472
Drug: 24 months
Normalized name: influenza virus vaccine ts 2015-2016 (6-24 months)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 months of dual antiplatelet therapy (DAPT)